http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이영열(Young Yiul Lee),이광호(Kwang Ho Lee),채동완(Dong Wan Chae),한진석(Jin Suk Han),김성권(Sung Kwon Kim),이정상(Jung Sang Lee),이문호(Mun Ho Lee) 대한내과학회 1989 대한내과학회지 Vol.36 No.2
N/A Although immunologic mechanism including complement activation as a pathophysiology of Korean hemorrhagic fever has been suggested, measurable complement activation resulting in the formation of anaphylatoxins, C3a, C4a and C5a, has not been verified to date. The purpose of this study was to determine if biologically active products of complement appear during the course of Korean hemorrhagic fever, and to investigate which of the two complemene activation pathways, classic or alternative, is activated. The levels of C3a C4a and C5a in serial plasma samples obtained from 15 patients with Korean hemorrhagic fever were measured by radioimmunoassay. The mean plasma C3a concentration, as well as C4a and C5a, in patients was significantly higher than normal control during all phases of Korean hemorrhagic fever. The mean plasma C level was highest in patients in the febrile and convalescent phase and this phenomenon was consistently observed with C4a and C5a. Poor correlations were observed between the levels of C3a, C4a and C5a, respectively. It was concluded that complement activation undoubtedly occurred in Korean hemorrhagic fever, and this strongly suggested that biologically active products of complement were generated during the enormous activation of the complement system via both the classic and alternative pathways.
성인의 T - lymphoblastic Lymphoma 의 임상상과 Modified LSA2 - L2 화학요법의 치료성적
김인순(In Soon Kim),한동수(Dong Soo Han),최영춘(Young Chun Choi),이영열(Young Yiul Lee),정태준(Tae Joon Chung),최일영(Il Young Choi),고영혜(Young Hyeh Ko),이중달(Jung Dal Lee) 대한내과학회 1989 대한내과학회지 Vol.37 No.1
N/A Adult T-lymphoblastic lymphoma was first described by Barcos and Lukes in 1974. It is famous for early systemic metastasis and should be treated systematically as soon as possible. We diagnosed 8 adult T-lymphoblasic lymphomas by means of clinical manifestation, tissue biopsy and their immunophenotyping from May 1986 to September 1988. Seven cases were treated with an aggressive regimen, the modified LSA2-L2 protocol. The results were as follows: 1) The median age in the group was 24 years (range 17 -35). 2) At diagnosis, all patients had mediastinal involvement, and 5 patients had bone marrow involvement. Three patients demonstrated malignant cells in the peripheral blood. 3) Six patients were positive for Tdt stain and 4 patients were CD7 (+). 4) Complete clinical response was attained in all patients with induction therapy including cytoxan, vincristine, and adriamycin. 5) Two complete responders who did not take the prescribed chemotherapeutic medication and CNS prophylaxis have had relapses in the CNS and testis. In summary, adult T-lymphoblastie lymphoma is a very aggressive and systemic disease. Systemic chemotherapy with CNS prophylaxis, such as the modified LSA2-L2 protocol, should be recommended.
이영열 한양대학교 의과대학 2000 한양의대 학술지 Vol.20 No.2
Hematologic malignancies and some solid tumors have been effectively treated by conventional doses of chemotherapy. However, those patients are confronted by relapse due to minimal residual disease. Therefore, more effective treatment stratege is needed for cure or increase of survival. Hematopoietic stem cell transplantation(HSCT) is a kind of organ transplantation and can be used as a curable treatment stratege in some malignant patients. HSCT can be classifed into bone marrow transplantation and peripheral blood stem cell transplantation according to the source of hematopoietic stem cells. If donor of hematopoietic stem cell is the healthy person, we call it allogeneic HSCT, and if donor of hematopoietic stem cell is the patient himself, that is autologous HSCT. In this article, HSCT is briefly introduced for the easy access to clinicians.
김혁,안명주,오석중,이영열,김인순,정태준,최일영,오미란,임호준,이항,김신규 한양대학교 의과대학 1999 한양의대 학술지 Vol.19 No.1
Responses to chemotherapy correlate with the increased dose of chemotherapeutic agents in some cancers, e.g. breast cancer, Ewing's sarcoma, Hodgkin's disease(HD) and non-Hodgkin's lymphoma(NHL), then for the improvement of the chemotherapy responsiveness, high-dose chemotherapy(HDCT) was proposed. But, it's application was limited due to complications, especially bone marrow suppression. HDCT and succeeding autologous peripheral blood stem cell transplantation(APBSCT) was introduced to overcome this problem. This study was designed to determine the clinical pictures including clinical parameters and the responsiveness of HDCT followed by APBSCT in Hanyang University Hospital. Ten patients were enrolled. They were 8 adults (3 breast cancers, 3 multiple myelomas, 1 HD, 1 NHL) and 2 children (1 acute myelogenous leukemia (AML), 1 neuroblastoma). Mobilization chemocherapy(MCT) followed by Granulocyte Colony Stimulating Factor(G-CSF) was administered to mobilize stem cells from bone marrow to peripheral blood. The stem cells were collected by using CS-3000 and cryopreserved at -196℃ with programmed controlled rate freezer as the mixture with 10% dimethyl sulfoxide(DMSO). HDCT was administered and cryopreserved peripheral stem cells were infused on day 0 as planned. Patients' mean age was 41 years old. After induction chemotherapy three patients achieved complete response and 5 partial response. The median time for bone marrow recovery after MCT was 11.5 days for neutrophil(〉500/㎣) and 4.8 days for platelet(〉20,000/㎣). There were three cases of neutropenic fever and one case of gingivitis. After HDCT with APBSCT, one patient was converted partial response to complete response, and one patient achieved complete response after HDCT without induction chemotherapy. The median time for bone marrow recovery was 12.7 days for neutrophil(〉500/㎣) and 14.7 days for platelet(〉20,000/㎣). Eight patients developed neutropenic fever and required systemic antibiotics. Transfusion was required 1.6 pints for packed red cell and 23.4 pints for platelet concentrates. Toxicity consisted mainly of vomiting, diarrhea, and mucositis which were mild. HDCT with APBSCT can be performed safely with minimal complications. For the evaluation of the exact role of HDCT with APBSCT in malignant diseases, further studies are required as a large scale of patients and lung-term follow up.
이준수,변재원,최일영,오호석,백창희,정성진,최정혜,안명주,이영열,김인순,이웅수,김신규 한양대학교 의과대학 2001 한양의대 학술지 Vol.21 No.2
Chronic lymphocytic leukemia(CLL) is a neoplastic disease characterized by the accumulation of small mature-appearing lymphocytes in the blood, bone marrow, lymph nodes, and spleen, resulting in enlargement of the lymph nodes and spleen, and decreased bone marrow function. CLL has an average incidence of 30 percent of all leukemia cases in Western countries, but it is extremely rare in Asia. T cell origin (T-CLL) is a very rare CLL subtype, as ninety five percent of CLL have B-cell markers. It has an aggressive clinical course. We have experienced a case of T4-CLL, which was confirmed by immunophenotyping panel. A 54-year-old male was admitted for abdominal distension which persisted for one month. A physical examination showed 5 finger sized splenomegaly and cervical lymphadenopathy on both side. The white blood cell count was 131,000/(L with 82% morphologically mature lymphcoytes with many smudge cells. A bone marrow aspirate revealed 61% lymphocytes morphologically similar to peripheral lymphocytes, which were small with a high nuclear cytoplasmic ratio and round to oval nuclei with absent or small inconspicuous nucleoli. The immunophenotyping study of lymphcoytes revealed phenotype of CD3(+), CD4(+), but CD8(-), CD19(-), CD20(-).
Hydroxyurea 에 의한 진성다혈구증의 치료 1 예
이재호,김경수,김인순,최일영,이영열,최대홍 대한내과학회 1987 대한내과학회지 Vol.33 No.4
Polycythemia vera is a chronic myeloproliferative disease characterized by a clonal proliferation that arises at the 1evel of the pluripotent stem cell. Therapeutic modalities of polycythemia vera have included phlebotomy alone or phlehotomy supplemented by myelosuppressive agents. But each therapeutic modality has had inevitable complications such as thrombosis, leukemia and/or other non-hematologic malignancies. These findings emphasized the desirability of developing an effective non-carcinogenic, myelosuppressive agent for the treatment of polycythemia vera. It appears that hydroxyurea has no increased risk of mutagenic transformation to patients of polycythemia vera, although longer follow-up is still necessary. Presented here, a 45-year old patient with polycythemia vera who achieved clinical and hematologic improvement by hydroxyurea.